AKT inhibitor capivasertib reverses EVI1‑driven resistance to venetoclax in acute myeloid leukaemia
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 3 × K562_Control vs 3 × K562_EVI1_OE vs 3 × MOLM14_control vs 3 × MOLM14_EVI1_OEGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- AKT inhibitor capivasertib reverses EVI1-driven resistance to venetoclax in acute myeloid leukaemiaBritish journal of haematology · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE326738_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1446826 and SRA study SRP688595. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9637965 K562_Control_rep1 K562_Control
- GSM9637966 K562_Control_rep2 K562_Control
- GSM9637967 K562_Control_rep3 K562_Control
- GSM9637968 K562_EVI1_OE1 K562_EVI1_OE
- GSM9637969 K562_EVI1_OE2 K562_EVI1_OE
- GSM9637970 K562_EVI1_OE3 K562_EVI1_OE
- GSM9637971 MOLM14_control_rep1 MOLM14_control
- GSM9637972 MOLM14_control_rep2 MOLM14_control
- GSM9637973 MOLM14_control_rep3 MOLM14_control
- GSM9637974 MOLM14_EVI1_OE1 MOLM14_EVI1_OE
- GSM9637975 MOLM14_EVI1_OE2 MOLM14_EVI1_OE
- GSM9637976 MOLM14_EVI1_OE3 MOLM14_EVI1_OE
- GSE300177 Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 194 samples shares resistance, inhibitor, leukaemia
- GSE330399 Molecular and Structural Basis of Pan-Resistance to BTK Inhibitors and Degraders 100 samples shares resistance, inhibitor
- GSE286827 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy 87 samples shares resistance, inhibitor
- GSE211434 Diverse immune suppressing cancer communications with myeloid cells prevent T cell activation and recruitment and provide resistance to cell cycle inhibitor therapy 81 samples shares resistance, inhibitor
- GSE316734 Characterization of sensitivity and resistance mechanisms to DHX9 inhibitor in endometrial and ovarian cancer cell lines 48 samples shares resistance, inhibitor
- GSE225060 Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response (RNA-Seq). 33 samples shares resistance, inhibitor
- GSE314603 Transcriptomic profiling of MCL-1 inhibitor response and resistance in mantle cell lymphoma cell lines and patient PBMCs 20 samples shares resistance, inhibitor
- GSE268699 Genes expression alterations associated with resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer 18 samples shares resistance, inhibitor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.